• Daiichi Sankyo filed Nov. 12, 2026, for Japanese approval of Enhertu for HER2-expressing advanced or recurrent uterine carcinosarcoma.
• The application uses already available results from STATICE, a Japanese investigator-led Phase 2 trial enrolling 34 previously treated patients across seven institutions.
• Enhertu demonstrated clinical efficacy, becoming the first anti-HER2 therapy to show such benefit in this patient population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.